Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Journal of Immunotherapy and Precision Oncology|August 29, 2022
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University ExperienceDylan J Martini, T Anders Olsen, Subir Goyal, et al.
Clinical Genitourinary Cancer|March 5, 2024
Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive NephrectomyEdouard H Nicaise, Benjamin N Schmeusser, Adil Ali, et al.
The Oncologist|February 3, 2026
Clinical outcomes of Lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancerMargo Brooke Gerke, Akshay Bedmutha, Angelo Marra, et al.
Frontiers in Oncology|July 5, 2021
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint BlockadeT Anders Olsen, Dylan J Martini, Subir Goyal, et al.
Frontiers in Oncology|July 26, 2021
Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint InhibitorsDylan J Martini, T Anders Olsen, Subir Goyal, et al.
The Oncologist|June 7, 2023
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint InhibitorsGregory E Sanda, Julie M Shabto, Subir Goyal, et al.
Clinical Genitourinary Cancer|December 19, 2021
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma PatientsDylan J Martini, Sean T Evans, Yuan Liu, et al.
Nature Communications|June 13, 2022
High throughput, label-free isolation of circulating tumor cell clusters in meshed microwellsMert Boya, Tevhide Ozkaya-Ahmadov, Brandi E Swain, et al.
The Oncologist|July 11, 2026
Novel Risk Scoring System for Patients with Metastatic Castration Resistant Prostate Cancer Treated with Lutetium-177-PSMA-617Margo B Gerke, Angelo Marra, Michelle Jayaraj, et al.
The Oncologist|June 22, 2021
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsDylan J Martini, Subir Goyal, Yuan Liu, et al.
Pageof 6